Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
Peringkat dalam Saham #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Harga Saham
$17.82
Terakhir disinkronkan: 2026-09-11
Kapitalisasi Pasar
$32.43B
Perubahan (1 hari)
0.83%
Perubahan (1 tahun)
-25.31%
Negara
JP
Perdagangan Daiichi Sankyo Company, Limited (4568)

Kategori

Jumlah saham beredar untuk Daiichi Sankyo Company, Limited (4568)
Jumlah saham beredar per June 2026: 1.82B
Menurut laporan keuangan terbaru dan harga saham Daiichi Sankyo Company, Limited, jumlah saham beredar saat ini adalah 1.82B. Pada akhir March 2024, perusahaan memiliki 1.92B saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Daiichi Sankyo Company, Limited (4568) dari 2000 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
2026 (TTM) 1.82B -4.04%
2025 1.90B -1.09%
2024 1.92B 0.02%
2023 1.92B 0.02%
2022 1.92B -1.17%
2021 1.94B -0.23%
2020 1.94B 0.02%
2019 1.94B -1.87%
2018 1.98B -1.68%
2017 2.01B -2.60%
2016 2.07B -2.08%
2015 2.11B 0.00%
2014 2.11B 0.00%
2013 2.11B 0.00%
2012 2.11B 0.00%
2011 2.11B 0.00%
2010 2.11B -0.63%
2009 2.13B -1.83%
2008 2.16B -1.02%
2007 2.19B -0.67%
2006 2.20B 69.91%
2005 1.30B -1.92%
2004 1.32B -1.30%
2003 1.34B -1.36%
2002 1.36B -0.67%
2001 1.37B -0.73%
2000 1.38B 0.00%
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
892.40M -50.96%
US
2.44B 34.09%
US
1.77B -2.68%
US
796.00M -56.26%
CH
0.00 -100.00%
US